MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+49-6151-720
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees51,039
Next Earnings DateN/A
OptionableOptionable
Merck KGaA (FRA:MRK) Frequently Asked Questions
What is Merck KGaA's stock symbol?
Merck KGaA trades on the FRA under the ticker symbol "MRK."
What price target have analysts set for MRK?
20 equities research analysts have issued 12 month price objectives for Merck KGaA's shares. Their predictions range from €82.00 to €111.00. On average, they expect Merck KGaA's stock price to reach €100.53 in the next twelve months. This suggests a possible upside of 9.5% from the stock's current price. View Analyst Price Targets for Merck KGaA.
What is the consensus analysts' recommendation for Merck KGaA?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck KGaA in the last year. There are currently 1 sell rating, 14 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Merck KGaA.
Has Merck KGaA been receiving favorable news coverage?
News coverage about MRK stock has been trending somewhat negative this week, according to InfoTrie. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Merck KGaA earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the healthcare company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Merck KGaA.
Who are some of Merck KGaA's key competitors?
Some companies that are related to Merck KGaA include 1933 Industries (TGIF), Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACG), Applied Biosciences (APPB), Biome Grow (BIO), Blueberries Medical (BBM), Cannabis Science (CBIS), Cannara Biotech (LOVE), Charlotte's Web (CWBHF), Choom (CHOOF), Cipher Pharmaceuticals (CPHRF), CLS Holdings USA (CLSH), Cosmos (COSM) and Curaleaf (CURLF).
What other stocks do shareholders of Merck KGaA own?
Who are Merck KGaA's key executives?
Merck KGaA's management team includes the folowing people:
- Dr. Stefan Oschmann, Chairman of Exec. Board & CEO (Age 62)
- Dr. Marcus Kuhnert, CFO & Member of Exec. Board (Age 51)
- Dr. Kai Beckmann, CEO of Performance Materials & Member of the Exec. Board (Age 54)
- Dr. Udit Batra, CEO of Life Science & Member of Exec. Board (Age 48)
- Ms. Belén Garijo López M.D., CEO of Healthcare & Member of the Exec. Board (Age 59)
What is Merck KGaA's stock price today?
One share of MRK stock can currently be purchased for approximately €91.80.
What is Merck KGaA's official website?
How can I contact Merck KGaA?
Merck KGaA's mailing address is Frankfurter Strasse 250, DARMSTADT, 64293, Germany. The healthcare company can be reached via phone at +49-6151-720.
MarketBeat Community Rating for Merck KGaA (FRA MRK)
MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
